Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | WNT3A | P56704 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220798 | 0.92 | MAPT (0.72) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2804156 | 0.87 | MRGPRX4 (0.78) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2063068 | 0.87 | SMN1; SMN2 (0.73) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17129585 | 0.85 | MAPT (0.67) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2814873 | 0.85 | SMN1; SMN2 (0.67) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13413496 | 0.84 | MAPT (0.66) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13448171 | 0.84 | MAPT (0.65) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13413479 | 0.84 | MAPT (0.58) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| Bicarbonate SCHEMBL5499350 | 0.84 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| Bicarbonate SCHEMBL5499351 | 0.84 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | MAPT 1012/4885SMN1; SMN2 2229/4885CYP1A2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.